OA03-RF01.07. Neoadjuvant Chemoimmunotherapy Versus Upfront Surgery for Clinical T2N0 Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis
Clicks: 2
ID: 325722
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #172 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background The role of neoadjuvant chemoimmunotherapy (nICT) in clinical T2N0 (cT2N0) esophageal squamous cell carcinoma (ESCC) remains controversial. Current guidelines recommend upfront surgery for this population, yet clinical staging inaccuracy frequently results in pathological understaging at surgery. This study aimed to evaluate the efficacy and oncological outcomes of nICT compared with upfront surgery in patients with cT2N0 ESCC. Methods We conducted a multicenter retrospective cohort study of 643 patients with cT2N0 ESCC treated between July 2016 and June 2025 at four institutions: Zhongshan Hospital of Fudan University, Zhongshan Hospital Center of Geriatric Medicine, Zhongshan Hospital Xiamen Branch, and Lu’an Affiliated Hospital of Anhui Medical University. Patients received either nICT followed by surgery (nICT group, n = 112) or upfront surgery alone (Surgery group, n = 651). Propensity score matching (PSM) at a 1:1 ratio was performed adjusting for age, sex, body mass index, comorbidities, ECOG performance status, and tumor location, yielding 112 matched pairs (N = 224). The primary endpoints were disease-free survival (DFS) and overall survival (OS). Pathological response was assessed in the nICT group using tumor regression grade (TRG). Results After PSM (112 pairs, N = 224), baseline characteristics were well balanced between groups (all SMD < 0.1). At a median follow-up of 41.8 months, nICT was associated with significantly improved DFS (HR = 0.556, 95% CI 0.360–0.859, P = 0.007) and OS (HR = 0.440, 95% CI 0.237–0.818, P = 0.008) compared with upfront surgery. The 3-year DFS rate was 70.8% in the nICT group versus 49.3% in the Surgery group, and 3-year OS rate was 86.7% versus 80.2%, respectively (Figure 1). In the nICT group, pCR was achieved in 26.8% (30/112), MPR in 60.7% (68/112), and T-downstaging in 63.4% (71/112) of patients; effective tumor regression (TRG 1–3) was observed in 88.4% (Figure 2). Notably, among surgery-alone patients, only 28.1% were correctly staged at final pathology, with 54.9% understaged and 45.5% harboring unexpected nodal metastasis, which was associated with significantly worse survival. Conclusion Neoadjuvant chemoimmunotherapy significantly improved DFS and OS compared with upfront surgery in patients with cT2N0 ESCC. The high clinical understaging rate observed in the surgery-alone group suggests that a substantial proportion of cT2N0 patients harbor occult advanced disease that benefits from neoadjuvant treatment. These findings from this multicenter analysis support extending the indication of neoadjuvant chemoimmunotherapy to cT2N0 ESCC.
| Reference Key |
openalex_W7203891659
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Xu Huang, Zitao Jian, Wenyi Xu, Runze You, Han Tang, Lijie Tan |
| Journal | diseases of the esophagus : official journal of the international society for diseases of the esophagus |
| Year | 2026 |
| DOI |
10.1093/dote/doag077.026
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.